Thursday, January 3, 2013

Hepatitis C - 2013 Interferon Free Combinations

Website Updates

2013 Interferon Free Combinations

Achillion: Poised For Growth And Now Is The Time To Buy
What is notable is that Achillion has 4 drugs in the mix; ACH-2684, 2928, 3102 and 1625. Each of which are showing strong promise at various phase I and II trials, and can either work independently or in combination in an oral fashion, not injections.

2013 Sofosbuvir (GS-7977)

The following two downloads are provided via NATAP's mailing list
Subscribe to the NATAP HCV Mailing List by email:
*with a subject line of subscribe
Learn more here

Nucleotide Polymerase Inhibitor Sofosbuvir plus Ribavirin for Hepatitis C
The standard treatment for hepatitis C virus (HCV) infection is interferon,which is administered subcutaneously and can have troublesome side effects.We evaluated sofosbuvir, an oral nucleotide inhibitor of HCV polymerase, in interferon-sparing and interferon-free regimens for the treatment of HCV infection.
Download Full Text Here

Exploratory Study of Oral Combination Antiviral Therapy for Hepatitis C
There is a need for interferon-free treatment regimens for hepatitis C virus (HCV) infection. The goal of this study was to evaluate ABT-450, a potent HCV NS3 protease inhibitor,
combined with low-dose ritonavir (ABT-450/r), in addition to ABT-333, a nonnucleoside NS5B polymerase inhibitor, and ribavirin, for the treatment of HCV infection
View PDF ---
nejmoa1208809.pdf 466K View
nejmoa1208809_appendix-1.pdf 115K View
nejmoa1208809_appendix.pdf 115K View

Chronic Hepatitis C Infection: Treat Now or Wait?

2013-Hepatitis C Full Text Articles

2013-HCV Abstract Corner

HCV Advocate - Top News of 2012
A milestone—GS-7977
Outbreaks of HCV in Health Care Settings
First National Helpline
DAA’s and Transplant Patients
and more........

In The News

Microbiotix Announces Exclusive Worldwide Licensing Agreement for HCV NS5B Non-Nucleoside Polymerase Inhibitors

Revolutionary techniques could help harness patients' own immune cells to fight disease

No comments:

Post a Comment